Biophytis Presents Obesity Program at SCWD Congress

Biophytis SA, a clinical-stage biotechnology company, showcased its OBA program at the 17th SCWD congress. The event brought together experts on sarcopenia and cachexia. Rob van Maanen, Biophytis's Chief Medical Officer, presented BIO101, a drug candidate aimed at reducing muscle mass loss induced by GLP-1 RAs in overweight and obese patients.

The Quinolia study on 58 adults showed a reduction in fat mass and potential muscle strength maintenance with 20-hydroxyecdysone. The phase 2 OBA study, set for 2025, will evaluate 164 obese patients using GLP-1 RAs. Primary efficacy focuses on muscle strength, with results anticipated by late 2025. Biophytis aims for regulatory approvals to commence trials in the US and Europe.